Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677754 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase 2 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 542
- Enrollment target
- 20
- Study locations
NCT01677754: Completed Phase 2 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
NCT01677754 is a Phase 2 study of Alzheimers Disease that has completed, run by Hoffmann-La Roche. The registered enrollment target is 542 participants, below the 3,923-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01677754, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 542 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in participants with moderate severity Alzheimer's disease. Participants who are taking background therapy of acetylcholinesterase inhibitors (AChEI) alone or in combination with memantine for at least 4 months before screening will be randomized to receive either one of two doses of RO4602522 or placebo for 12 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Memantine
- DRUG Rivastigmine
- DRUG Donepezil
- DRUG RO4602522
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- Meridien Research - Brooksville
- Brain Matters Research, Inc. - Delray Beach
- Neurologic Consultants, P.A. - Fort Lauderdale
- Galiz Research, LLC - Hialeah
- Miami Jewish Health Systems - Miami
- Medical Research Group of Central Florida - Orange City
- Compass Research East, LLC - Orlando
- Comprehensive Clinical Development, Inc.- St. Petersburg, FL - St. Petersburg
- Axiom Clinical Research of Florida - Tampa
- Premiere Research Institute - West Palm Beach
California
- Advanced Research Center, Inc.;In-Patient Unit - Anaheim
- Neurology Center of North Orange County - Fullerton
- Torrance Clinical Research - Lomita
- Artemis Institute for Clinical Research, LLC - San Diego
- Sharp Mesa Vista Hospital - San Diego
- San Francisco Clinical Research Center - San Francisco
- Neurological Research Inst - Santa Monica
Connecticut
- Yale University School Of Medicine - New Haven
- Research Center for Clinical Studies, Inc. - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2012-10-24 |
| Est. Completion | 2015-06-12 |
| Phase | Phase 2 |
What the finished NCT01677754 record still lists
NCT01677754 is an interventional study that assigns participants to a tested intervention. The registered 542 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01677754 names 20 study sites across 3 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01677754 about?
NCT01677754 is a clinical study titled "A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy". This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in participants with moderate severity Alzheimer's disease. Participants who are taking background therapy of acetylcholinesterase inhibitors (AChEI) alon...
What is the current status of trial NCT01677754?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 542 participants. The study started on 2012-10-24. Estimated completion is 2015-06-12.
What conditions does trial NCT01677754 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01677754?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG), Rivastigmine (DRUG), Donepezil (DRUG), RO4602522 (DRUG).
Who is sponsoring clinical trial NCT01677754?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01677754 being conducted?
This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01677754's enrollment target sits among peer trials
542 28th of 147 higher than 120 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04929223 · 542 participants · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI